Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Small Cell Lung Carcinoma 10Lung Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Cholangiocarcinoma 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Oropharyngeal Neoplasms 6Fallopian Tube Neoplasms 6Urinary Bladder Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Gallbladder Neoplasms 4Brain Neoplasms 4Adenocarcinoma of Lung 4Stomach Neoplasms 3Sarcoma 3Mouth Neoplasms 3Mesothelioma, Malignant 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma 3Urethral Neoplasms 2Triple Negative Breast Neoplasms 2Testicular Neoplasms 2Seminoma 2Salivary Gland Neoplasms 2Recurrence 2Prostatic Neoplasms 2Peritoneal Neoplasms 2

Interventions

Radiotherapy 9Doxorubicin 7pazopanib 5palbociclib 4Trabectedin 4Gemcitabine 4ribociclib 3pembrolizumab 3eribulin 3Magnetic Resonance Spectroscopy 3selinexor 2liposomal doxorubicin 2avelumab 2abemaciclib 2Sunitinib 2Radiation Dose Hypofractionation 2Radiation 2Immunoglobulin G 2Ifosfamide 2Docetaxel 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zimberelimab 1temsirolimus 1sotigalimab 1sodium thiosulfate 1sitravatinib 1silmitasertib 1sargramostim 1romidepsin 1regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Liposarcoma × Platinum × Clear all
NCT04213794 2025-02-20

TOASTIT

Mayo Clinic

Phase EARLY_PHASE1 Terminated
2 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Colonic Neoplasms, Fallopian Tube Neoplasms, Liposarcoma, Ovarian Neoplasms, Pelvic Neoplasms, Rectal Neoplasms, Rhabdomyosarcoma, Sarcoma, Stomach Neoplasms, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡